Dr. Jeffrey Crawford is the George Barth Geller Professor
for Research in Cancer and a principal investigator (PI) of the National
Clinical Trials Network (NCTN) LAPS Grant at the Duke Cancer Institute in
Durham, NC. He earned his M.D. from Ohio State University in 1974 and completed
his internship, residency, and hematology/oncology fellowship at Duke
University Medical Center. He served as the chief of the Division of Medical
Oncology for 10 years before assuming his current leadership role. He also served
as the chair of the National Comprehensive Cancer Network Myeloid Growth
Factors Panel for 15 years. Dr. Crawford’s research interests include new
treatment approaches to lung cancer, supportive care therapies including
hematopoietic growth factors and biosimilars, and agents that impact muscle
wasting.
Dr. Jeffrey Crawford is the George Barth Geller Professor
for Research in Cancer and a principal investigator (PI) of the National
Clinical Trials Network (NCTN) LAPS Grant at the Duke Cancer Institute in
Durham, NC. He earned his M.D. from Ohio State University in 1974 and completed
his internship, residency, and hematology/oncology fellowship at Duke
University Medical Center. He served as the chief of the Division of Medical
Oncology for 10 years before assuming his current leadership role. He also served
as the chair of the National Comprehensive Cancer Network Myeloid Growth
Factors Panel for 15 years. Dr. Crawford’s research interests include new
treatment approaches to lung cancer, supportive care therapies including
hematopoietic growth factors and biosimilars, and agents that impact muscle
wasting.